The FDA finally released its draft guidance on Decentralized Clinical Trials (DCTs). Is it everything we've been waiting for?
Highly anticipated FDA draft guidance on Decentralized Clinical Trials has been released
The 4 “I”s of Investigator Motivation – Impediments
In the introduction to this series about Investigator Motivation, the connection was drawn between Motivation and Momentum. It’s a cyclical effect in clinical trials where one can influence the other both in negative and positive ways. When both Motivation and Momentum are low, we find sites silently quitting the study. What brings them to this point? One piece of the puzzle is to identify and eliminate impediments that prevent the study from functioning optimally.
Decentralized Clinical Trials – a site’s perspective
"Decentralized clinical trials" is the new buzz phrase in the clinical research community. The advancement of decentralized trials has been accelerated due to the pandemic and the need to do more remotely. As this new era dawns in clinical research, we need to exercise caution before diving headfirst.
DCTs. A site’s perspective
"Decentralized clinical trials" is the new buzz phrase in the clinical research community. The reality for sites who have done these studies is that there are several challenges that have not been adequately addressed to date.
Clinical Research 